Sunday, April 18, 2010

Analysis of Vectibix(R) Study Using New Gene Technology Helps to Advance Prospects for Personalized Medicine

--Nine Genes Beyond KRAS Investigated As Potential Predictive Biomarkers For Metastatic Colorectal Cancer Therapy --ABSTRACT NUMBER: LBA 8791

THOUSAND OAKS, Calif., April 18, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced detailed results from a new biomarker analysis of the pivotal Phase 3 “408” trial of Vectibix(R) (panitumumab) plus best supportive care (BSC) compared to BSC alone. The analysis used massively parallel, next-generation sequencing technology to investigate whether mutations in nine genes known to be mutated in colorectal cancer, including the previously unanalyzed exon 3 mutation of the KRAS gene, are predictive of response to Vectibix in metastatic colorectal cancer (mCRC). Highlighted results were presented at the opening press conference at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C.

Posted in Press Releases

Monday, April 12, 2010

Amgen Highlights Biomarker and Preclinical Data to be Presented at American Association for Cancer Research (AACR) Annual Meeting

Key RANK Ligand Preclinical Data and Vectibix Biomarker Data Will Be Presented

THOUSAND OAKS, Calif., April 12, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced that results from several preclinical studies investigating potential new cancer agents and a comprehensive biomarker analysis will be presented at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C. from April 17 - 21, 2010.

Posted in Press Releases